



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 038602/1023

In re patent application of

KOUHARA, HARUHIKO et al.

Serial No. 09/731,660

Filed: December 8, 2000

For: ADAPTOR PROTEIN FRS2 AND RELATED PRODUCTS AND METHODS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231

**Box SEQUENCE**

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 038602/1023

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

May 30, 2001  
Date

James A. Coburn  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021



## SEQUENCE LISTING

<110> KOUHARA, HARUHIKO  
SPIVAK-KROIZMAN, TALY  
LAX, IRIT  
SCHLESSINGER, JOSEPH

<120> ADAPTOR PROTEIN FRS2 AND RELATED PRODUCTS AND METHODS

<130> 038602/1023

<140> 09/731,660

<141> 2000-12-08

<150> 08/980,523

<151> 1997-12-01

<150> 60/032,093

<151> 1996-12-03

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 508

<212> PRT

<213> Homo sapiens

<400> 1

Met Gly Ser Cys Cys Ser Cys Pro Asp Lys Asp Thr Val Pro Asp Asn  
1 5 10 15

His Arg Asn Lys Phe Lys Val Ile Asn Val Asp Asp Asp Gly Asn Glu  
20 25 30

Leu Gly Ser Gly Val Met Glu Leu Thr Asp Thr Glu Leu Ile Leu Tyr  
35 40 45

Thr Arg Lys Arg Asp Ser Val Lys Trp His Tyr Leu Cys Leu Arg Arg  
50 55 60

Tyr Gly Tyr Asp Ser Asn Leu Phe Ser Phe Glu Ser Gly Arg Arg Cys  
65 70 75 80

Gln Thr Gly Gln Gly Ile Phe Ala Phe Lys Cys Ala Arg Ala Glu Glu  
85 90 95

Leu Phe Asn Met Leu Gln Glu Ile Met Gln Asn Asn Ser Ile Asn Val  
100 105 110

Val Glu Glu Pro Val Val Glu Arg Ser Ser His Gln Thr Glu Leu Glu ~  
115 120 125

Val Pro Arg Thr Pro Arg Thr Pro Thr Thr Pro Gly Leu Gly Ala Gln  
130 135 140

Asn Leu Pro Asn Gly Tyr Pro Arg Tyr Pro Ser Phe Gly Asp Ala Ser  
 145 150 155 160  
 Ser His Pro Ser Ser Arg His Pro Ser Val Gly Ser Ala Arg Leu Pro  
 165 170 175  
 Ser Val Gly Glu Glu Ser Thr His Pro Leu Leu Val Ala Glu Glu Gln  
 180 185 190  
 Val His Thr Tyr Val Asn Thr Thr Gly Val Gln Glu Glu Arg Lys Asn  
 195 200 205  
 Arg Ala Ser Val His Val Pro Pro Glu Ala Arg Val Ser Asn Ala Glu  
 210 215 220  
 Ser Asn Thr Pro Lys Glu Glu Pro Ser Asn Pro Glu Asp Arg Asp Pro  
 225 230 235 240  
 Gln Val Leu Leu Lys Pro Glu Gly Val Arg Phe Val Leu Gly Pro Thr  
 245 250 255  
 Pro Val Gln Lys Gln Leu Met Glu Lys Glu Lys Leu Glu Gln Leu Gly  
 260 265 270  
 Lys Asp Pro Val Ser Gly Ser Gly Ala Gly Asn Thr Glu Trp Asp Thr  
 275 280 285  
 Gly Tyr Asp Ser Asp Glu Arg Arg Asp Val Pro Pro Val Asn Lys Leu  
 290 295 300  
 Val Tyr Glu Asn Ile Asn Gly Leu Ser Ile Pro Ser Ala Ser Gly Val  
 305 310 315 320  
 Arg Arg Gly Arg Leu Thr Ser Thr Ser Thr Ser Asp Thr Gln Asn Ile  
 325 330 335  
 Asn Asn Ser Ala Gln Arg Arg Pro Ala Leu Leu Asn Tyr Glu Asn Leu  
 340 345 350  
 Pro Ser Leu Pro Pro Val Trp Glu Ala Arg Lys Leu Ser Arg Asp Glu  
 355 360 365  
 Asp Asp Asn Leu Gly Pro Lys Thr Pro Ser Leu Asn Gly Tyr His Asn  
 370 375 380  
 Asn Leu Asp Pro Met His Asn Tyr Val Asn Thr Glu Asn Val Thr Val  
 385 390 395 400  
 Pro Ala Ser Ala His Lys Ile Asp Tyr Ser Lys Arg Arg Asp Cys Thr  
 405 410 415  
 Pro Thr Val Phe Asn Phe Asp Ile Arg Arg Pro Ser Leu Glu His Arg  
 420 425 430  
 Gln Leu Asn Tyr Ile Gln Val Asp Leu Glu Gly Gly Ser Asp Ser Asp  
 435 440 445

Asn Pro Gln Thr Pro Lys Thr Pro Thr Thr Pro Leu Pro Gln Thr Pro  
450 455 460

Thr Arg Arg Thr Glu Leu Tyr Ala Val Ile Asp Ile Glu Arg Thr Ala  
465 470 475 480

Ala Met Ser Asn Leu Gln Lys Ala Leu Pro Arg Asp Asp Gly Thr Ser  
485 490 495

Arg Lys Thr Arg His Asn Ser Thr Asp Leu Pro Met  
500 505

<210> 2

<211> 114

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: PTB domain of  
IRS-1

<400> 2

Asp Thr Gly Pro Gly Pro Ala Phe Lys Glu Val Trp Gln Val Ile Leu  
1 5 10 15

Lys Pro Lys Gly Leu Gly Gln Thr Lys Asn Leu Ile Gly Ile Tyr Arg  
20 25 30

Leu Cys Leu Thr Ser Lys Thr Ile Ser Phe Val Lys Leu Asn Ser Glu  
35 40 45

Ala Ala Ala Val Val Leu Gln Leu Met Asn Ile Arg Arg Cys Gly His  
50 55 60

Ser Glu Asn Phe Phe Phe Ile Glu Val Gly Arg Ser Ala Val Thr Gly  
65 70 75 80

Pro Gly Glu Phe Trp Met Gln Val Asp Asp Ser Val Val Ala Gln Asn  
85 90 95

Met His Glu Thr Ile Leu Glu Ala Met Arg Ala Met Ser Asp Glu Phe  
100 105 110

Arg Pro

<210> 3

<211> 129

<212> PRT

<213> Homo sapiens

<400> 3

Asp Thr Val Pro Asp Asn His Arg Asn Lys Phe Lys Val Ile Asn Val  
1 5 10 15

Asp Asp Asp Gly Asn Glu Leu Gly Ser Gly Val Met Glu Leu Thr Asp  
                   20                  25                  30  
 Thr Glu Leu Ile Leu Tyr Thr Arg Lys Arg Asp Ser Val Lys Trp His  
                   35                  40                  45  
 Tyr Leu Cys Leu Arg Arg Tyr Gly Tyr Asp Ser Asn Leu Phe Ser Phe  
                   50                  55                  60  
 Glu Ser Gly Arg Arg Cys Gln Thr Gly Gln Gly Ile Phe Ala Phe Lys  
                   65                  70                  75                  80  
 Cys Ala Arg Ala Glu Glu Leu Phe Asn Met Leu Gln Glu Ile Met Gln  
                   85                  90                  95  
 Asn Asn Ser Ile Asn Val Val Glu Glu Pro Val Val Glu Arg Ser Ser  
                   100                  105                  110  
 His Gln Thr Glu Leu Glu Val Pro Arg Thr Pro Arg Thr Pro Thr Thr  
                   115                  120                  125  
 Pro

<210> 4  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide

<400> 4  
 Val Tyr Glu Asn Ile Asn Gly Leu Ser Ile Pro Ser Ala Ser Gly Val  
       1                  5                  10                  15

<210> 5  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
           peptide

<400> 5  
 Phe Val Leu Gly Pro Thr Pro Val Gln Lys  
       1                  5                  10

<210> 6  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Consensus  
peptide

<400> 6

Met Gly Ser Cys Cys Ser  
1 5

<210> 7

<211> 4

<212> PRT

<213> Homo sapiens

<400> 7

Asn Tyr Glu Asn  
1

<210> 8

<211> 4

<212> PRT

<213> Homo sapiens

<400> 8

Asn Tyr Val Asn  
1